-
Sarepta, Lysogene Announce Exclusive License Agreement for LYS - SAF302, a Late- stage Gene Therapy for the Treatment of MPS IIIA; Grant of Option Rights to an Additional CNS Gene Therapy Candidate
2018 Oct 26, 3:38amRead More...Sarepta Therapeutics, Inc. (NASDAQ: SRPT) announced today it has signed a license agreement with Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, for the development of a gene therapy, LYS-SAF302, to...
-
$5 Billion Oceania Cannabis Consumer Market
2018 Oct 25, 5:01pmRead More...Fueled by Canadian Imports, Australia’s Medical Market Anchors the Region’s Cannabis Industry New Frontier Data, today’s authority in data, analytics and business intelligence on the global cannabis industry, announces the publication of The Oceania Cannabis Report, 2018 Industry...
-
162% Increase In U.S. Legal Cannabis Cultivation Electricity Consumption By 2022
2018 Oct 25, 4:43pmRead More...U.S. cultivation consumed 1.1 million megawatt hours of electricity, generated 472 thousand tons of carbon in 2017 New Frontier Data, the authority in data, analytics and business intelligence on the global cannabis industry, in partnership with Resource Innovation Institute and Scale Microgrid...
-
